Loading
Recommendation to use a lower initiation threshold for vasopressin / Septic Shock / Vasopressin · Phase 4 Trial
ClinicalTrials.gov · August 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a completed Phase 4 pragmatic cluster-randomized trial comparing lower versus higher initiation thresholds for vasopressin in septic shock, enrolling 3,959 participants with 28-day all-cause mortality as the primary outcome. No results are posted in this registry record, and the trial's findings remain unpublished.
Phase 4, Interventional, Randomized, Crossover, Single masking, Treatment purpose. Septic Shock; age from 18 Years. Intervention: Septic shock treatment strategy involving a lower threshold…; Septic shock treatment strategy involving a higher threshol…. Compared with: Higher initiation threshold for vasopressin addition to first-line vasopressors. n = 3,959. 13 sites: United States.
This is a completed Phase 4 pragmatic cluster-randomized trial comparing lower versus higher initiation thresholds for vasopressin in septic shock, enrolling 3,959 participants with 28-day all-cause mortality as the primary outcome. No results are posted in this registry record, and the trial's findings remain unpublished.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a completed but unpublished Phase 4 pragmatic trial of 3,959 participants examining vasopressin initiation thresholds in septic shock; results are not yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06217562). This is a study registration, not published results. Lead sponsor: Intermountain Health Care, Inc.. Recruitment status: COMPLETED. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 3959 participants (ACTUAL). Conditions: Septic Shock. Interventions: DRUG: Vasopressin; OTHER: Recommendation to use a lower initiation threshold for vasopressin; OTHER: Recommendation to use a higher initiation threshold for vasopressin. Primary outcome measures: 28-day all-cause mortality , 28 days. Brief summary: Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.